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Summary The site of action of aminoglutethimide (AG) has been investigated. An initial study was performed
on 10 postmenopausal patients with advanced breast cancer who had taken 1000mg AG per day and 20mg
hydrocortisone (HC) twice daily (b.d.) for >3 months. There was a 15.5 +5.6 s.e.-fold rise in 17-OH
progesterone and a 4.9+0.9 s.e.-fold rise in 4A androstenedione but no rise in cortisol or oestrone 30min after
short Synacthen tests. These results suggested that peripheral aromatisation was a more important site of AG
action than adrenal desmolase, and that adrenal 11,B hydroxylase was inhibited. Since aromatase is more
sensitive than desmolase to AG in vitro, lower doses of AG alone (i.e. without HC) were assessed for endocrine
effects in 13 further post-menopausal women with advanced breast cancer. All of these patients tolerated
125 mg AG b.d., but 3 could not tolerate the conventional maximum dose. Oestrone levels on 125 mg AG b.d.
were suppressed below pretreatment levels and were not significantly different from those on 500mg AG b.d.
alone, or with the addition of HC. Oestradiol levels were suppressed to a similar extent.
Dehydroepiandrosterone sulphate (DHA-S) levels were not suppressed by AG alone, but fell on addition of
HC. The endocrine results show low dose AG alone is an effective and well tolerated inhibitor of the
peripheral production of oestrogens in postmenopausal patients. Therapeutic trials are now possible. DHA-S
is not a marker of AG effect.
Aminoglutethimide (AG) in combination with
hydrocortisone (HC) is an effective endocrine
therapy in advanced postmenopausal breast cancer,
producing a response rate and duration similar to
tamoxifen (Smith et al., 1981). AG was introduced
into the treatment of breast cancer as an inhibitor
of adrenal steroid production. One site of action is
the earliest step in the adrenal conversion of
cholesterol to pregnenolone (20,22 desmolase)
(Dexter et al., 1967). AG treatment regimes are
currently designed to inhibit this step and HC is
added in replacement doses to prevent a reflex rise
in ACTH secretion (Santen et al., 1974). However,
AG has another site of action, the inhibition of the
conversion of androgens to oestrogens in peripheral
tissues tissues (Santen et al., 1978) (Figure 1), which
is the main source of oestrogen in the post-
menopausal woman (Grodin et al., 1973). AG can
also inhibit 11-fJ-hydroxylase (Faglia et al., 1971).
One of the factors limiting the use of AG is the
side effects that occur at conventional dose levels
(250mg 4 times a day). In one series of 190 patients,
58% had transient side effects, 9.5% needed to
reduce the dose and 5% discontinued the drug
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(Harris et al., 1982). Similar results are reported by
Santen et al. (1977). Graves & Salhanick (1979)
showed that aromatisation in vitro is at least 10
times more sensitive than desmolase to inhibition
by AG. We have therefore studied the site of action
of AG in postmenopausal patients with advanced
breast cancer receiving AG and HC therapy in
conventional doses and investigated the endocrine
effects of low doses of AG alone.
Patients and methods
Synacthen tests
Ten postmonopausal patients with advanced breast
cancer, who were taking AG 250mg 4 x daily and
hydrocortisone 20mg b.d. (8am, 8pm), were studied
after 3 months of therapy. Tetracosactrin (250,pg;
Synacthen, Ciba) was given i.m. in the gluteus
maximus. The patient was resting before the
injection and for 30min afterwards. Blood samples
were taken before and 30min after the injection.
These tests were performed to assess the need for
cortisol replacement during stress, but oestrone,
dehydroepiandrosterone sulphate (DHA-S), A4
androstenedione and 17 OH progesterone were also
measured.
A normal cortisol response was considered to be
an initial cortisol level > 138nM I-1 and a rise of
2200nM 1- , with a plasma level of 2500nM 1
at 30min, irrespective of initial levels.
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Figure 1 Sites of action of aminoglutethimide. 20,22 desmolase (DE); 3,Bol dehydrogenase, A4-A5 isomerase
(3b); aromatase (AR) =means inhibition by aminoglutethimide. 17 a OH progesterone is converted to 11
deoxycortisol by 21 hydroxylase; 11 deoxycortisol is converted to cortisol by 1 Il, hydroxylase.
Low dose aminoglutethimide alone
Thirteen postmenopausal patients (not the 10
already described) with progressive advanced breast
cancer were studied. Ten were spontaneously
menopausal. Nine had been given previous
endocrine therapy with 3 partial responses and 2
patients showing disease stabilisation. Two had
received adjuvant chemotherapy. Their ages ranged
from 37-76yr (median 58yr). The last menstrual
period was from 1 to 15yr previously (median IOy).
The tumour free interval ranged from 0-12yr,
median 20 months. Sites of disease were soft tissue
(4), pleura (4), bone (5), nodes (3), lung (1) and
ascites (1). Weight ranged from 47-79kg (median
65kg).
Each of the patients had a blood sample taken
between 9.30 and 11 am before the start of
treatment with AG, after they had been off any
other endocrine therapy for at least 1 month. They
then started treatment with AG 125mg b.d. (8 am,
8 pm) for one week. For the second week the dose
was doubled to 250mg b.d. for the third and fourth
weeks it was doubled to 500mg b.d. Those patients
who could not tolerate this dosage took AG
250mg, 8am, 500mg 8pm. HC 20mg b.d. (8am,
8pm) was added for the 4th week. Blood samples
were taken weekly for 4 weeks and all samples from
each patient were measured in one assay. Thus the
hormone values measured are those occurring after
1 week of therapy with each dose increment. The
patients were to be withdrawn from the study if
there was any evidence of disease progression or
unexpected side effects.
Hormone assays
All blood samples were collected in lithium heparin
tubes and the plasma was stored at -20°C until
assay.
Oestrone, oestradiol, DHA-S, 4A androstenedione
and 17 OH-progesterone were all measured by
immunoassay as described previously (Harris et al.,
1982a, b). However, in this work a chromatography
step was included in the oestrone analysis prior to
immunoassay. This involved the use of Sephadex
LH-20 columns (7cm long, in short-form pasteur
pipettes) with methylene chloride:methanol (95:5) as
solvent (Murphy, 1971). The results were corrected
according to the recovery of - 103c.p.m. of [2,4,6,7
-3H] oestrone (Amersham International), which
was added to serum samples 18h before extraction.
Cortisol was measured using reagents provided by
the WHO Matched Reagent Scheme and according
to WHO recommended methodology (WHO
Manual 1981). The intra- and inter-assay
coefficients of variation were 7.2 and 14.6
respectively.
Results
Synacthen tests
A4 androstenedione and 17 OH progesterone had
risen markedly (Figure 2) 30min after Synacthen.
Their respective rises as a percentage of baseline
levels were 489+85 s.e. (median 450) and 1546+563
s.e. (median 810) (P<0.01, paired t-tests, Mann-
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Figure 2 A4 androstenedione and 170H progesterone
levels after Synacthen. Samples were taken before and
30min after 250gg Synacthen i.m. All patients were
receiving 250mg AG 4 x daily plus 20mg HC b.d.
marginal significance between the rise in A4
androstenedione and the rise in 17 OH
progesterone (Figure 3) (r =0.562, P =0.055).
Only 1 patient showed a normal rise in cortisol
levels. As a group, these did not change significantly
(paired t-test, Mann-Whitney U test). In 4/10
patients, the post-stimulation levels were
<500nM 1-' (Figure 4). Oestrone and DHA-S
levels did not change significantly. These results
suggested that the desmolase enzyme (Figure 1) was
not the main site of AG action as there was a large
rise in the steroids beyond the supposed site of
block.
Low dose aminoglutethimide alone
Side effects and response Thirteen patients entered
the study. One withdrew after 1 week because she
developed supraventricular tachycardia (not known
to be drug-related). The other 12 patients had their
dose increased to 250 mg twice a day. One
developed a progressive pleural effusion and was
withdrawn. Another patient had "blackouts" but
tolerated the lower dose of 125mg b.d, to which
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Figure 3 The relationship of A4 androstenedione to
170H progesterone levels before and after Synacthen
tests. 170H progesterone v A4 androstenedione in
individual patients before Synacthen tests (@). 170H
progesterone v A4 androstenedione in individual
patients after Synacthen tests (0) (r=0.562, P=0.055).
HC was added. She has had stable disease for >6
months. Ten patients had their dose increased to
500mg b.d. Two could not tolerate the dose and
reduced the dose to 250mg a.m., 500mg p.m.
The results are thus described for 13 patients in
week 1, 12 patients in week 2, 10 patients in week 3
and 8 patients in week 4. Three patients were
maintained on lower doses of AG and had HC
added.
Because patients with recurrent disease were
being studied, the protocol of drug administration
was designed so that all the patients would be on
maximally tolerated doses of AG plus HC by 1
month from the start of the study. Thus, response
to low dose AG alone could not be assessed but
4/11 patients who continued AG responded (1
complete response, 1 partial response, 2 disease
stabilisations for >6 months).
Low dose aminoglutethimide alone
Endocrine results Oestrone levels were significantly
suppressed in all 13 patients (P=0.015) by the
lowest dose of AG alone (125mg b.d.) (Figure 5).
Increasing doses and addition of HC did not
suppress oestrone further (Table I). Oestradiol
suppression paralleled oestrone suppression (Figure
5).624 A.L. HARRIS et al.
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Figure 4 Cortisol, oestrone and DHA-S levels after Synacthen. Samples were taken before and 30min after
250jug Synacthen i.m. All patients were receiving 250mg AG 4 x daily plus 20mg HC b.d.
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Figure 5 Endocrine effects of incremental low dose aminoglutethimide alone and after the addition of
hydrocortisone. Results are means +s.e. at each point. P values are unpaired t tests comparing the effects of
the given dose with the pretreatment values. The hormone levels were measured after the patients had been on
the given dose of drugs for week. Dosage was increased at weekly intervals.
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Table I Oestrone results as a percentage of pre-treatment
levels
Aminoglutethimide dosage (mg b.d.)
500+
125 250 500 hydrocortisone
Oestrone levels
(% of baseline)
Mean 50 63 49 49
SD 20 24 29 22
There are no significant differences between any columns.
DHA-S levels were not suppressed by any dose of
AG, but fell by 75% when HC was added (Figure
5). Cortisol levels were not affected by AG alone
and did not rise when HC was added (Figure 5). A4
androstenedione and 17 OH progesterone levels
rose progressively as the dose of AG was increased
(Figures 5 and 6). After the addition of HC, the
levels fell to levels which were not significantly
different to basal values.
Patients not tolerating all dosage increments
The 3 patients who did not have the maximum
dose of AG of 1000mg per day were given HC as
well as continuing on their maximum tolerated
dose. Their results were quantitatively and
qualitatively similar to other patients. Thus, HC did
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not produce further oestrone or oestradiol
suppression and DHA-S concentrations only fell on
addition of HC. A4 androstenedione and 17 OH
progesterone fell to pretreatment values 1 week
after addition of HC.
Discussion
The results of Synacthen tests on patients receiving
conventional dose AG and HC show that one
putative site of AG action (at the 20,22 desmolase)
is readily overcome by exogenous adrenal
stimulation. The study was undertaken to assess
whether patients on AG therapy could synthesise
additional cortisol when under stress. Within 36h of
stopping HC and AG, the pituitary-adrenal axis
returns to normal responsiveness to stress (Worgul
et al., 1982). However, we have shown that there is
no increase in cortisol levels after Synacthen, which
suggests that additional HC may be necessary in
the interim period.
The marked rise in 17 OH progesterone with no
increase in cortisol suggests that 11 # hydroxylase is
inhibited (Figure 1). Faglia et al. (1971) also
suggested this may occur. The block could also be
at the 21 hydroxylase site, since this enzyme
converts 17 OH progesterone to 11 deoxycortisol,
the substrate that is converted to cortisol 11
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Figure 6 Effects of incremental aminoglutethimide dose on A4 androstenedione levels. Each symbol
represents a different patient. Pre treatment values are shown to the left of each column and values after 1
week of treatment with the given dose are shown on the right. Dosage was increased weekly.626 A.L. HARRIS et al.
hydroxylase. However, Taylor et al. (1978) showed
that 11 deoxycortisol levels rise in patients taking
AG, which suggests that 11 hydroxylase is the
more likely site of block.
Heterozygotes for congenital adrenal hyperplasia
with partial 21 hydroxylase deficiency show a
marked rise in 17 OH progesterone after Synacthen
tests, although not to the levels found in our
patients (Lee & Gareis, 1975; Mauseth et al., 1980).
Samojlik & Santen (1978) showed that A4
androstenedione and 17 OH progesterone were not
significantly suppressed by AG and HC, although
the precursors DHA and 17 OH pregnenolone were
markedly suppressed. They suggested that this
phenomenon could be explained by increased
activity of 3fol dehydrogenase. However, in our
study with Synacthen the percentage rise in 17 OH
progesterone is much greater than the rise in A4
androstenedione and there is a marginally
significant correlation with the rise in A4
androstenedione. 11/3 hydroxylase inhibition with
the accumulation of the precursor 17 OH
progesterone is an alternative explanation for the
rise in A4 androstenedione.
Vermeulen (1976) studied 10 normal
postmenopausal women on no treatment and found
a 5-fold increase in 17 OH progesterone and a 1.8-
fold increase in A4 androstenedione on Synacthen
stimulation. These rises are less than half of those
we found. Oestrone also rose in those patients,
although in our patients there was no rise in
oestrone. Kruyt & Rolland (1982) also found
increases in A4 androstenedione and 17 OH
progesterone in normal women on no treatment,
but again these were less in amplitude than those
found in our study. This difference is probably
because the normal women were not taking AG
and our patients were. Because of the block in
conversion of 17 OH progesterone to cortisol, the
levels of 17 OH progesterone rose higher in our
own patients, as did A4 androstenedione levels.
The low dose AG study was undertaken because
the failure of oestrone to increase on Synacthen
stimulation suggested that the main site of action of
AG for inhibiting oestrone production is the
peripheral aromatase system rather than adrenal
steroidogenesis. The lowest dose of AG studied
suppressed oestrone and oestradiol levels as much
as the full dose of 500mg b.d. with HC 20mg b.d.
The oestrone suppression was maintained in the
presence of increasing A4 androstenedione levels in
weeks 1, 2 and 3 after starting AG. The increase in
A4 androstenedione and 17 OH progesterone with
increasing dosage of AG, without a fall in DHA-S,
suggests that desmolase is not inhibited and that
with increasing AG there is increasing blockade of
1l,B hydroxylase and/or increasing activity of 3Pol
dehydrogenase. Aromatase appears to be maximally
inhibited by the lowest dose.
The progressive increases are unlikely to be due
to time on treatment, since the Synacthen tests
show the adrenal can respond within 30min to a
change in stimulus, and within one week of adding
a replacement dose of HC the 17 OH progesterone
and A4 androstenedione levels had returned to
normal. AG has a plasma half-life of 7-12h
(Murray et al., 1979), which should lead to the
attainment of a new steady state within one week of
each dose increment. AG induces its own
metabolism (Murray et al., 1979), but this probably
occurs within the first week, as no changes in
plasma levels were detected between 1 and 12 weeks
of therapy (Murray et al., 1979).
There was no significant suppression of DHA-S
until HC was added. AG alone does not maintain
DHA-S suppression and DHA-S cannot therefore
be used as a marker for the endocrine effects of AG.
Several studies that have used DHA-S as a monitor
for AG (Samojlik & Santen 1980; Coombes et al.,
1982; Murray et al., 1981) will need to be re-
assessed. Santen et al. (1982) found that in clinical
non-responders to AG therapy, DHA-S levels were
higher than in responders. This is unlikely to reflect
differences in AG levels, but rather the effects of
HC. Similarly, the potency of the D-isomer was
compared with 1000mg of racemic AG and
considered to be twice as active (Samojlik &
Santen, 1980) but our results show that 250mg of
racemic AG is as potent as 1000mg. The relative
potency of D-aminoglutethimide in vivo is thus
unknown.
The cortisol levels remained the same after
addition of HC, showing that 20mg twice a day
was a replacement dose for the patients studied.
The fall in 17 OH progesterone and A4
androstenedione is probably due to suppression of
the increased ACTH drive following inhibition of
llI# hydroxylase by AG. Increased ACTH drive is
likely because a block of conversion of 17 OH
progesterone to cortisol should produce a rise in 17
OH progesterone and a fall in cortisol, unless
increased ACTH drive raised precursors sufficiently
to overcome the block and reach a new steady state
with normal cortisol and raised precursors.
All 13 patients tolerated the lowest dose of AG
without side effects but 3/11 patients who had dose
increments could not tolerate the full dose. These
endocrine studies show that in patients with
advanced breast cancer, AG acts biochemically by
inhibiting the conversion of A4 androstenedione to
oestrone in peripheral tissues, rather than by
adrenal suppression. Peripheral aromatisation is
much more sensitive than the adrenal desmolase to
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These studies provide the endocrine basis for
further investigation of the clinical response to low
dose AG alone. This dosage regimen should be less
toxic, as well as producing a novel manipulation of
the endocrine environment (a rise in androgens and
fall in oestrogens). The twice daily low dose regime
may be useful in adjuvant therapy and combination
endocrine therapy as well as in advanced disease.
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